# X-Cor Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/x-cor-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Boston, US
- Website: http://www.xcortherapeutics.com
- Total disclosed funding: $2.6M
- Latest round: Seed (Nov 12, 2020)
- Investors on record: 4

## About

X-Cor Therapeutics, Inc. is an innovative medical device company specializing in the development of a groundbreaking solution for the extracorporeal removal of carbon dioxide (CO2) from patients experiencing respiratory distress.Founded in 2017 and headquartered in Boston, US, X-Cor Therapeutics, Inc. focuses on creating advanced medical devices that improve patient care in respiratory failure scenarios. The company has undergone strategic developments to enhance its product offerings and has engaged in funding rounds to support its growth initiatives. The team includes founders Brian Chang, Jayon Wang, and Steven Keller, with Jayon Wang currently serving as CEO. The company raised USD 2.6 million in its Seed funding round, led by Alira Health, with total funding amounting to USD 2.6 million.X-Cor Therapeutics specializes in the development of a pioneering medical device that enables the extracorporeal removal of carbon dioxide from patients suffering from hypercarbic respiratory failure. The key product is a hybrid consumable cartridge that effectively removes CO2 using ultra-low blood flow rates of less than 300 ml/min, making it a less invasive alternative to traditional methods that require higher flow rates and specialized interventions. Their target customers include hospitals and healthcare providers treating respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD) and cystic fibrosis, aiming to widen accessibility to their devices across the global healthcare market.While specific revenue figures are not disclosed, X-Cor Therapeutics operates on a business model that likely involves direct sales to healthcare facilities and partnerships with medical institutions. The revenue structure is expected to include B2B engagements where hospitals procure the CO2 removal devices directly. Pricing is anticipated to be on a per-unit basis for the hybrid cartridges, complemented by ongoing revenue from consumable supplies used routinely in treatment.X-Cor Therapeutics plans to leverage the recent Seed funding of USD 2.6 million, raised in November 2020, to further develop its product line and expand into new markets. The funds will support the introduction of new products designed for improved CO2 removal and the enhancement of existing technologies. The company is targeting expansion into various geographical regions to increase market presence, aiming to establish its products in healthcare systems that address respiratory illnesses effectively.

## Funding rounds

- Seed, Nov 12, 2020, $2.6M — The Graduate Syndicate, Good Growth Capital, Alira Health, PiSA BioPharm, Inc.

## Investors

- The Graduate Syndicate (https://capitalatlas.ai/funds/the-graduate-syndicate) — Seed
- Good Growth Capital (https://capitalatlas.ai/funds/good-growth-capital) — Seed
- Alira Health — Seed
- PiSA BioPharm, Inc. — Seed